In conjunction with this year’s Skin Cancer Awareness Month, HemOnc Today presented seven important updates in melanoma/skin cancer prevention and detection.
In addition, Healio Dermatology highlights recent popular articles from cutaneous oncology research centers and academic institutions.
Seven important updates for Skin Cancer Awareness Month
Sancy Leachman, MD, PhD, chair of the dermatology department at Oregon Health & Science University, delivered a two-part talk at HemOnc Today New York that focused on the importance of early detection of melanoma. Read more.
Tumor thickness, location of primary melanoma affects recurrence rates
Researchers from QIMR Berghofer Medical Research Institute in Australia suggest that approximately 13% of patients with a high-risk primary melanoma may develop recurrence within 2 years, and informed clinical follow-up should include understanding the patterns and risk factors of disease recurrence. Read more.
More evidence needed from dermatologic surgical registries to define best practices
“We were surprised by how little has been done to define ‘quality’ in dermatologic surgery. Our goal for this review is to raise awareness so that dermatologic surgeons will take an active role in developing relevant definitions of quality care to benefit patients,” Conroy Chow, MD, of the department of dermatology, Loma Linda University, said in an interview with Healio Dermatology. Read more.
Time to recurrence of metastatic melanoma not associated with survival rates
In patients with metastatic melanoma, the timing of advanced disease was not associated with the timing of first distant recurrence, according to a multicentric cohort study. Read more.
Immunosuppression independent risk factor for poor outcomes when adjusted for tumor stage
Immunosuppression was associated with a threefold to fourfold increase for disease-related poor outcomes, including local recurrence, nodal metastasis and in-transit metastasis, in low-stage cutaneous squamous cell carcinomas, according to a 10-year retrospective cohort from researchers at Tufts Medical Center. Read more.